Menu Search
Equities

Phio Pharmaceuticals Corp

44R1:MUN

Phio Pharmaceuticals Corp

Actions
  • Price (EUR)2.99
  • Today's Change0.00 / 0.00%
  • Shares traded250.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Oct 31 2024 07:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

  • Revenue in USD (TTM)0.00
  • Net income in USD-8.68m
  • Incorporated2011
  • Employees8.00
  • Location
    Phio Pharmaceuticals Corp11 APEX DRIVE, SUITE 300A, PMB 2006MARLBOROUGH 01752United StatesUSA
  • Phone+1 (508) 767-3861
  • Fax+1 (508) 767-3862
  • Websitehttps://phiopharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.